Company intelligence / Profile preview

Heptech

Rio de Janeiro, Rio de Janeiro, Brazilheptech.eu ↗

Ownership: Private
Development stage: Other

Overview

Heptech has developed safer bovine heparin alternatives, including a safe bovine heparin (SBH) comparable to porcine heparin, a pharmacopeia-compliant bovine low molecular weight heparin (B-LMWH), and an innovative low anticoagulant heparin that reduces tumor growth and metastasis. The company is advancing these through scale-up, IP protection, and partnership development. No published human clinical results yet.

Therapeutic areas: OncologyCardiovascular
Modalities: Heparin-derived productsSulfated polysaccharides
Industry: Biotech

Drug pipeline

2 assets

safe bovine heparin

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

FAPERJ – funding/grants partner for R&D scale-upSEBRAE – CATALISA ICT project participant for product development support

Beyond the preview

Go deeper on Heptech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heptech.

Explore the full profile